Compare BIO-TECHNE Corp (TECH) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Block Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Block Inc trades at $75.35 (market cap $45.70B). The key difference: Block Inc is far larger — about 4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Block Inc for 78 Days on average.
| TECH | XYZ | |
|---|---|---|
Market Cap | $11.37B | $45.70B |
Volume | 3,153,511 | 3,000,312 |
Sector | Health | Technology |
52-Week High | $72.61 | $84.85 |
52-Week Low | $43.31 | $49.04 |
Typical Hold Time | 63 Days | 78 Days |
Enterprise Value | $11.40B | $40.61B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
XYZ trades at $75.21, down 1.76% today, with a bearish technical signal and mixed earnings performance. The company shows strong revenue growth from $17.5B in 2022 to $24.2B in 2025, though net margins remain thin at 1.43%. Recent news highlights expansion of Square and Cash App partnerships, while analysts maintain a bullish consensus with a $97.47 price target representing 30% upside potential.
XYZ presents a growth story with expanding merchant platforms and strategic partnerships, but faces execution risks amid thin profitability. The stock trades at elevated valuation multiples (P/E 135.84) while showing improving cash flow trends. Near-term catalysts include Q3 2026 earnings release on November 3, 2026, with institutional sentiment remaining positive despite recent insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
